Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 18/20 | 0.70 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446012 | 1.00 | P2RY1 (0.70) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL3445848 | 0.90 | P2RY1 (0.62) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL3445844 | 0.90 | P2RY1 (0.62) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1425263 | 0.88 | NPC1 (0.73) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1425261 | 0.88 | NPC1 (0.73) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1425259 | 0.88 | NPC1 (0.73) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1424516 | 0.87 | NPC1 (0.62) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1425097 | 0.87 | NPC1 (0.65) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1424519 | 0.87 | NPC1 (0.62) | P2RY1P2RY14NPC1RAB9AMAPT | |
| SCHEMBL1425101 | 0.87 | NPC1 (0.65) | P2RY1P2RY14NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | claimed |
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | P2RY1 1/4885P2RY14 10/4885NPC1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.